Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
adult patients, 18-70 years of age
hepatitis C, genotype 1 or 4, of over 6 months duration
treatment-naïve
negative pregnancy test; female patients of childbearing age and male patients with female partners of childbearing age must use two forms of contraception during treatment and following the last dose of ribavirin in accordance with locally approved label for ribavirin
You may not be if
pregnant or breast feeding females or male partners of pregnant females
previous interferon or ribavirin based therapy or investigational anti-HCV agent
systemic antiviral therapy with established or perceived activity against HCV \</=3 months prior to first dose of study drug
hepatitis A or B, or HIV infection
history or evidence of medical condition associated with chronic liver disease other than HCV
Clareo Health | A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4
